Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.

David J. Kuter(Harvard University), Janet L. Nichol(Amgen (United States)), Reggie Kelly(Amgen (United States)), Martin R. Schipperus(Rijnland Ziekenhuis), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), James N. George(University of Oklahoma), James B. Bussel(Cornell University), Jorge J. Nieva(University of Southern California), Jenny Christal(Amgen (United States)), François Lefrère(Hôpital Necker-Enfants Malades), Matthew Guo(Eisai (United States)), Alan Lichtin(Cleveland Clinic), M. C. Kappers‐Klunne(Erasmus MC), Jeffrey S. Wasser(Community Cancer Center), Emanuelle Bourgeois(Hôpital Claude Huriez), Roger M. Lyons(Hematology Oncology Associates)
Blood
November 16, 2006
10.1182/blood.v108.11.476.476
Cited by 30

Related Papers

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
|Blood|2008|2.6k
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
|Science|2009|1.5k
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
|Blood Advances|2019|1.1k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
|PubMed|2001|803